Montréal
,
Canada
24 - 28 June 2023
International Society on Thrombosis and Haemostasis (ISTH 2023)
Presentation schedule and materials
The congress symposium is no longer available
Sunday, 25 June 2023
POSTER
In vitro thrombin generation in the presence of emicizumab sequence identical analogue (emi-SIA) and concizumab
Kjalke M1; Rose TH1; Porstmann T2
POSTER
Higher thrombin generation is predicted when switching directly from emicizumab to Mim8 in patients with hemophilia A
Kreilgaard M1; Lund J2; Matytsina I3
POSTER
In vitro assessment of clinical coagulation assays in the presence of concizumab
Augustsson C1; Strandberg K1; Kjalke M2
Monday, 26 June 2023
POSTER
Feasibility of self-ultrasound scanning of the knee joint in untrained individuals: Can artificial intelligence help?
Tyrrell PN1; Blanchette V2; Eltawil F3; Kras S4; Brink Scholz C5; Zak M6; Roth J7
POSTER
A usability study assessing handling and preference of the concizumab pen-injector in patients with haemophilia and caregivers
Rasmussen NK1; Berg BG1; Christensen ASL1; Neergaard JS1; Shah S2; Ter Borch G1; Sparre T1
Tuesday, 27 June 2023
ORAL PRESENTATION
Investigating downstream effects of concizumab using a mathematical modelling approach
Leiderman K1; Mast AE2; Dockal M3; Kjlake M4; Miyazawa K5
ORAL PRESENTATION
Evaluation of concizumab in hemophilia A using microfluidic flow assays
Jewell M1; Wufsus A2; Pallini C3; Dockal M4; Kjalke M5; Neeves KB6
ORAL PRESENTATION
Concizumab prophylaxis in patients with haemophilia A or B without inhibitors: Efficacy and safety results from the primary analysis of the phase 3 explorer8 study
Chowdary P1; Angchaisuksiri P2; Apte S3; Chan AKC4; Jacobsen SH5; Jimenez-Yuste V6; Thaung Zaw JJ7; Wheeler AP7; Windyga J8; Eichler H9
ORAL PRESENTATION
Health-related quality of life, treatment burden and patient preference in patients with haemophilia A/B without inhibitors on concizumab prophylaxis: Results from the phase 3 explorer8 study
Young G1; Benson G2; Eichler H3; Mahlangu J4; Neergaard J5; Odgaard-Jensen J5; Thaung Zaw JJ5; Sathar J6; Tran H7; Matsushita T8on behalf of the explorer8 investigators
ORAL PRESENTATION
Pooled safety results from the multidose explorer studies of concizumab in patients with haemophilia
Eichler H1; Matsushita T2; Angchaisuksiri P3; Castaman G4; Eliraqi G5; Kavakli K6; Ogden MC5; Rasmussen JS5; Wheeler A7; Shapiro A8; Astermark J9
POSTER
Rationale and design of pathfinderreal: A prospective, non-interventional study assessing joint health in adults with haemophilia A after switching to prophylaxis with turoctocog alpha pegol (N8-GP)
Ay C1; Benitez O2; Gidley G3; Liles D4; Mancuso ME5; Matino D6; Nagao A7; Nemes L8; Waller J9; Oldenberg J10
POSTER
Weight-band dosing with Mim8: Using modelling to support a streamlined approach to haemophilia A treatment
Kreilgaard M1; Matytsina I1; Persson P1
Wednesday, 28 June 2023
ORAL PRESENTATION
Mim8 interference on the measurement of FVIII standard and extended half-life products using selected FVIII chromogenic Assays
Pickering W1; Robinson M1; Cogswell C1; Clausen WHO2; Ezban M3
Keywords